Use of valsartan in post-myocardial infarction and heart failure patient

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue SUPPL. 1, 2006, Pages

  Liu, Peter P ^a   Maggioni, Aldo ^b   Velazquez, Eric J ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b ANMCO RESEARCH CENTER   (Italy)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Heart failure; Hypertension; Val HeFT trial; VALIANT trial; Valsartan

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; PLACEBO; RAMIPRIL; RENIN; TRANDOLAPRIL; VALSARTAN;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HORMONAL REGULATION; HUMAN; HYPERTENSION; LONG TERM CARE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC OUTPUT, LOW; HUMANS; MYOCARDIAL INFARCTION; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; VALINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33748643987     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.019     Document Type: Article

References (29)

1. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-62.
2. American Heart Association. Heart disease and stroke statistics - 2005 update. Dallas, Texas: American Heart Association, 2005.
3. Velazquez EJ, Francis GS, Armstrong PW et al. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. Eur Heart J 2004;25:1911-19.
4. Packer M, Cohn JN, Abraham WT et al. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83:1A-38A.
5. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2001;38:2101-13.
6. Hunt SA, Baker DW, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Available at http://www.acc.org/clinical/guidelines/failure/index.pdf
7. Rouleau J-L, Packer M, Moyé L et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24:583-91.
8. Re RN. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 2004;1:42-7.
9. Unger T. Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications. JRAAS 2001;2(Suppl 2):S4-S7.
10. Adams KJ. Pathophysiological role of renin-angiotensin-aldosterone system and sympathetic nervous system in heart failure. Am J Health-Sys Pharm 2004;61:S4-S13.
11. The CONSENSUS investigators. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
12. Flather MD, Yusuf S, Køber L et al. for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-81.
13. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. N Engl J Med 1992;327:669-77.
14. Roig E, Perez-Villa F, Morales M et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000;21:53-7.
15. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42.
16. Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993; 71(Suppl):3A-11A.
17. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.
18. Pitt B, White H, Nicolau J et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005;46:425-31.
19. Pitt B, Williams G, Remme W et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001; 15:79-87.
20. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
21. Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
22. Maggioni AP, Anand I, Gottlieb SO et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414-21.
23. Maggioni AP, Latini R, Carson PE et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548-57.
24. Wong M, Staszewsky L, Latini R et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002;40:970-5.
25. Latini R, Masson S, Anand I et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106:2454-8.
26. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
27. Kintscher U, Unger T. Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers. Acta Diabetol 2005;42:S26-S32.
28. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with Type 2 diabetes mellitus. Thromb Res 2006; 117:385-92.
29. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004;43:2216-23.